在恶性瘤中向CD47/SIRPα通路:最近的进展,困难和未来的前景
Chenyang Jiang1,2, Hao Sun3, Zhongxing Jiang1
1Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Frontiers in oncology
|July 23, 2024
概括
最近对CD47-SIRPα向疗法的临床试验失败,包括在肌肉发育综合征中使用Magrolimab和Evorpacept,引发了人们对其开发可行性的担忧. 本综述探讨了挑战,并提出了促进CD47-SIRPα药物开发的解决方案.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药物开发 药物开发
背景情况:
- CD47是一种先天性免疫检查点,与PD-1相比,CD47已成为一个有前途的治疗标.
- 早期的临床开发和行业投资为CD47向疗法带来了乐观的看法.
研究的目的:
- 审查开发CD47-SIRPα向药物的挑战.
- 分析导致最近临床试验失败的因素.
- 讨论CD47-SIRPα药物开发的未来前景和解决方案.
主要方法:
- 对CD47-SIRPα药物开发的文献综述.
- 对最近的临床试验结果 (Magrolimab,Evorpacept) 的分析.
- 讨论行业趋势和投资格局.
主要成果:
- 最近的第3阶段 (ENHANCE) 和第2阶段 (ASPEN-02) 试验中,在肌肉发育综合征 (MDS) 中,针对CD47向治疗的治疗报告失败.
- 这些挫折使人们对瘤学中向CD47的临床实用性产生了重大怀疑.
- CD47-SIRPα阻断作为单一疗法或组合疗法的疗效需要进一步研究.
结论:
- 开发针对CD47-SIRPα的药物面临重大障碍.
- 了解复杂的瘤微环境和免疫逃避机制至关重要.
- 未来的策略可能涉及组合疗法,新的目标识别或精细的患者选择,以克服当前的挑战.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K


